ArticleTherapeutic advances in medical oncology2022
Real-world experience with capmatinib in
Article in Therapeutic advances in medical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy.Clinical and experimental medicine · 2025Article
- Comprehensive management of MET tyrosine kinase inhibitor-induced peripheral edema in patients withTranslational lung cancer research · 2025Review
- Real world experience with MET inhibitors in MET exon 14 skipping mutated non-small cell lung cancer: largest Indian perspective.Discover oncology · 2025Article
- Article
- Intracranial response to capmatinib after progression on crizotinib in a patient withTranslational lung cancer research · 2024Article
- Effective treatment ofAME case reports · 2024Article
- My battle with cancer. Part 1.Oncoscience · 2024Review
- Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.Future oncology (London, England) · 2024Article
- Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.Clinical lung cancer · 2023Article
- Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations.International journal of molecular sciences · 2023Article
- The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.Cancers · 2023Review
- Evaluation of [Pharmaceutics · 2023Article
- Article
- Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives.Cancer management and research · 2023Review
- Survival outcomes and prognostic factors of lung cancer patients with theFrontiers in oncology · 2023Article
- Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors.Targeted oncology · 2022Article
- Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis.OncoTargets and therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 20 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal-epithelial transition ( Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021. Results: Data from 81 patients with advanced Conclusion: In patients with
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.